Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

873 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH.
Vergori A, Cozzi-Lepri A, Matusali G, Colavita F, Cicalini S, Gallì P, Garbuglia AR, Fusto M, Puro V, Maggi F, Girardi E, Vaia F, Antinori A; HIV-VAC Study Group. Vergori A, et al. Among authors: maggi f. Viruses. 2022 Aug 3;14(8):1710. doi: 10.3390/v14081710. Viruses. 2022. PMID: 36016332 Free PMC article.
SARS-CoV-2 nasopharyngeal viral load in individuals infected with BA.2, compared to Alpha, Gamma, Delta and BA.1 variants: A single-center comparative analysis.
Mastrorosa I, Cozzi-Lepri A, Colavita F, Lalle E, Mazzotta V, Cimaglia C, Paulicelli J, Matusali G, Fabeni L, Carletti F, Rosati S, Vita S, Giannico G, Piselli P, Biliotti E, Moghazi SA, Mosti S, Girardi E, Nicastri E, Garbuglia AR, Maggi F, Vaia F, Antinori A. Mastrorosa I, et al. Among authors: maggi f. J Clin Virol. 2022 Dec;157:105299. doi: 10.1016/j.jcv.2022.105299. Epub 2022 Sep 26. J Clin Virol. 2022. PMID: 36183546 Free PMC article.
Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
Mazzotta V, Cozzi Lepri A, Colavita F, Rosati S, Lalle E, Cimaglia C, Paulicelli J, Mastrorosa I, Vita S, Fabeni L, Vergori A, Maffongelli G, Carletti F, Lanini S, Caraffa E, Milozzi E, Libertone R, Piselli P, Girardi E, Garbuglia A, Vaia F, Maggi F, Nicastri E, Antinori A; INMI COVID-19 Outpatient Treatment Study Group. Mazzotta V, et al. Among authors: maggi f. J Med Virol. 2023 Jan;95(1):e28186. doi: 10.1002/jmv.28186. Epub 2022 Oct 7. J Med Virol. 2023. PMID: 36184918 Free PMC article.
Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination.
Matusali G, Petruccioli E, Cimini E, Colavita F, Bettini A, Tartaglia E, Sbarra S, Meschi S, Lapa D, Francalancia M, Bordi L, Mazzotta V, Coen S, Mizzoni K, Beccacece A, Nicastri E, Pierelli L, Antinori A, Girardi E, Vaia F, Sette A, Grifoni A, Goletti D, Puro V, Maggi F. Matusali G, et al. Among authors: maggi f. Vaccines (Basel). 2023 Sep 28;11(10):1541. doi: 10.3390/vaccines11101541. Vaccines (Basel). 2023. PMID: 37896943 Free PMC article.
Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients.
Minosse C, Matusali G, Meschi S, Grassi G, Francalancia M, D'Offizi G, Spezia PG, Garbuglia AR, Montalbano M, Focosi D, Girardi E, Vaia F, Ettorre GM, Maggi F. Minosse C, et al. Among authors: maggi f. Vaccines (Basel). 2023 Oct 28;11(11):1656. doi: 10.3390/vaccines11111656. Vaccines (Basel). 2023. PMID: 38005988 Free PMC article.
Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine.
Picchianti-Diamanti A, Navarra A, Aiello A, Laganà B, Cuzzi G, Salmi A, Vanini V, Maggi F, Meschi S, Matusali G, Notari S, Agrati C, Salemi S, Di Rosa R, Passarini D, Di Gioia V, Sesti G, Conti F, Spinelli FR, Corpolongo A, Chimenti MS, Ferraioli M, Sebastiani GD, Benucci M, Li Gobbi F, Santoro AP, Capri A, Puro V, Nicastri E, Goletti D. Picchianti-Diamanti A, et al. Among authors: maggi f. Vaccines (Basel). 2023 Nov 2;11(11):1684. doi: 10.3390/vaccines11111684. Vaccines (Basel). 2023. PMID: 38006015 Free PMC article.
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study.
Vergori A, Matusali G, Cimini E, Bordi L, Borrelli P, Lanini S, Palazzi R, Paulicelli J, Mariotti D, Mazzotta V, Notari S, Casetti R, Francalancia M, Rosati S, D'Abramo A, Mija C, Mencarini P, Milozzi E, Caraffa E, Sica S, Metafuni E, Sorà F, Rago A, Siniscalchi A, Abruzzese E, Garzia M, Luzi G, Battistini R, Prosperini L, Cingolani A, Girardi E, Maggi F, Antinori A; OCTOPUS Study Group. Vergori A, et al. Among authors: maggi f. Vaccines (Basel). 2024 Jul 17;12(7):784. doi: 10.3390/vaccines12070784. Vaccines (Basel). 2024. PMID: 39066422 Free PMC article.
873 results